Status:
COMPLETED
The Moran AMD Genetic Testing Assessment Study
Lead Sponsor:
Paul S. Bernstein
Collaborating Sponsors:
National Eye Institute (NEI)
Conditions:
Age-Related Macular Degeneration
Genetic Testing
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
Eligibility Criteria
Inclusion
- Participants must be between 18 and 64 years of age.
- They must also be Caucasian as this genetic test is only validated in Caucasians.
- They can have a positive family history of AMD but this is not necessary.
Exclusion
- Personal history of AMD
- Non Caucasian
- Employee of the Moran or other eye care practice (likely to have more knowledge about AMD than a layperson)
- Personal history of prior genetic testing for AMD risk
- Anticipated cataract surgery in the upcoming year (can affect Macular Pigment measurement)
- Major psychiatric disorder
Key Trial Info
Start Date :
August 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 12 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05265624
Start Date
August 3 2022
End Date
July 12 2024
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah John A. Moran Eye Center
Salt Lake City, Utah, United States, 84132